AIM AIM ImmunoTech Inc.
Biological Products, (No Diagnostic Substances) · NYSE · SEC CIK 946644 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-18.8%
TTM net income YoY10.3%
TTM EPS YoY93.4%
Revenue 3-yr CAGR-22.2%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-12,800.0%
Net margin-15,526.4%
FCF margin—
EBITDA margin-11,853.8%
Returns
ROE-2,828.6%
ROA-185.4%
ROIC (approx.)—
Asset turnover0.01x
Leverage & solvency
Liabilities / assets27.4%
Debt / equity0.41x
Current ratio2.75x
Interest coverage-9.33x
Cash quality & payout
Operating cash flow / net income0.87x
Accruals ratio-25.0%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $88,000 | $170,000 | $202,000 | $141,000 | $135,000 |
| R&D expense | $3.92M | $6.20M | $10.94M | $6.99M | $7.67M |
| SG&A expense | $7.70M | $13.71M | $21.14M | $13.07M | $8.67M |
| Operating income | -$11.66M | -$19.77M | -$31.92M | -$19.92M | -$18.84M |
| Interest expense | $812,000 | $585,000 | — | — | $67,000 |
| Pretax income | -$13.96M | — | — | — | — |
| Net income | -$13.96M | -$17.32M | -$28.96M | -$19.45M | -$19.13M |
| EBITDA | -$11.63M | -$19.73M | -$31.88M | -$19.89M | -$18.18M |
| EPS (basic) | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 |
| EPS (diluted) | -8.62 | -30.92 | -0.60 | -0.40 | -0.40 |
| Weighted avg. shares (diluted) | 1.62M | 560,169 | 48.59M | 48.05M | 47.34M |
| Balance sheet | |||||
| Cash & equivalents | $2.98M | $1.70M | $5.44M | $27.05M | $32.09M |
| Short-term investments | $62,000 | $2.28M | $7.63M | $7.14M | $16.18M |
| Receivables | $7,000 | — | $1.18M | $1.68M | — |
| Current assets | $3.29M | $4.18M | $14.56M | $36.32M | $50.21M |
| PP&E, net | $71,000 | $108,000 | $127,000 | $195,000 | $4.05M |
| Intangibles | $1.66M | $2.59M | $2.31M | $1.94M | $1.97M |
| Total assets | $5.78M | $8.61M | $19.38M | $40.49M | $57.70M |
| Current liabilities | $6.22M | $9.54M | $8.65M | $1.36M | $673,000 |
| Short-term debt | $3.55M | $2.31M | — | — | — |
| Long-term debt | $927,000 | $2.81M | — | — | — |
| Total debt | $4.48M | $5.11M | — | — | — |
| Total liabilities | $15.56M | $9.93M | $9.15M | $2.02M | $820,000 |
| Shareholders' equity | -$9.78M | -$1.32M | $10.23M | $38.47M | $56.88M |
| Net debt | $1.49M | $3.41M | — | — | — |
| Shares outstanding | 3.07M | 655,262 | 49.10M | 48.08M | 47.99M |
| Cash flow statement | |||||
| Operating cash flow | -$10.96M | -$14.89M | -$21.27M | -$16.11M | -$13.96M |
| Capital expenditure | — | $18,000 | — | $86,000 | $41,000 |
| Free cash flow | — | -$14.91M | — | -$16.19M | -$14.01M |
| Investing cash flow | $1.85M | $4.71M | -$832,000 | $10.99M | -$631,000 |
| Financing cash flow | $10.39M | $6.44M | $485,000 | $80,000 | $8.19M |
| Depreciation & amortization | $37,000 | $37,000 | $39,000 | $38,000 | $659,000 |
| Stock-based compensation | $60,000 | $686,000 | $243,000 | $954,000 | $1.57M |
Free plan shows the latest 5 periods; Pro shows all 17 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.